pH-Dependent TFPI Antibody for Longer-Lasting Coagulation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hemophilia and platelet disorders, such as hemophilia A, hemophilia B, Bernard-Soulier Syndrome, and Glanzmann Thrombasthenia, are limited by frequent infusions and variable efficacy due to the short half-life of factor replacement therapies and the lack of antibodies targeting Tissue Factor Pathway Inhibitor (TFPI), which can enhance coagulation capacity.
Innovation Solution
Development of a pH-dependent antibody or antigen-binding fragment that specifically binds to TFPI, enhancing coagulation by inhibiting TFPI activity, thereby prolonging the antibody's half-life and reducing dosing frequency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If factor replacement therapy is used to treat hemophilia, then coagulation function is restored, but frequent infusions are required due to short half-life
Solution Approach 1:
The patent uses anti-TFPI antibody as an intermediary to indirectly restore coagulation function. Instead of directly replacing deficient clotting factors, the antibody neutralizes TFPI, which is the natural inhibitor of the extrinsic coagulation pathway. This mediator approach bypasses the short half-life limitation of direct factor replacement while achieving reliable coagulation restoration.
Solution Approach 2:
The patent changes the pharmacokinetic parameter of half-life by using a different therapeutic mechanism. The anti-TFPI antibody has a prolonged half-life compared to factor replacement products, fundamentally altering the duration parameter from days to weeks, thereby reducing infusion frequency while maintaining therapeutic efficacy.
2Reliability
If factor replacement therapy is administered frequently to prevent spontaneous bleeding, then bleeding episodes are reduced, but patient burden and cost increase
Solution Approach 1:
The patent transitions from frequent periodic infusions (2-4 times per week) to less frequent periodic infusions (every 2-4 weeks) by using an antibody with prolonged half-life. This redefines the periodic action interval, significantly reducing the time loss associated with frequent hospital visits and infusions while maintaining reliable protection against spontaneous bleeding.
3Reliability
If TFPI activity is neutralized to enhance coagulation capacity, then coagulation function is improved, but treatment options are limited by lack of approved antibodies
Solution Approach 1:
The patent describes a humanized antibody that is less immunogenic and can be produced with improved manufacturability. The humanization process makes the antibody more compatible with human immune systems, reducing the need for complex immunosuppression protocols and improving ease of manufacture and clinical deployment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The pH-dependent TFPI antibody exhibits a prolonged half-life of over 100 hours, potentially reducing the frequency of infusions and improving treatment compliance by stabilizing the coagulation pathway.
Implementation Method 1
the antibody exhibits pH-dependent antigen-binding characteristics
Data Source
Figure 1~2-1
Figure 3A~2-2
Figure 4~5
AI summary
The present invention provides an antibody or an antigen-binding fragment thereof that specifically binds to Tissue Factor Pathway Inhibitor (TFPI) in a pH-dependent manner. Also provided are nucleic acid molecules encoding the antibody, expression vectors and host cells for expressing the antibody, as well as methods for producing the antibody. Furthermore, the invention provides a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, and the use of the pharmaceutical composition in the manufacture of a medicament for the prevention and/or treatment of diseases including hereditary or acquired coagulation factor deficiency, Bernard-Soulier Syndrome, and Glanzmann Thrombasthenia.